February 25, 2021 News by Marisa Wexler, MS #ACTRIMS2021 – Better Strategies Needed to Help Socioeconomically Disadvantaged Patients Editor’s note: TheĀ Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25-27. Go here to see all the latest stories from the conference. People with multiple sclerosis (MS) who are less socioeconomically advantaged tend to have faster rates…
December 2, 2020 News by Steve Bryson, PhD Aubagio Slows Grey Matter, Whole Brain Atrophy in CIS, Study Finds Studied for the first time,Ā Aubagio (teriflunomide) slowed the loss of cortical grey matter and whole-brain volume in people with clinically isolated syndrome (CIS) during two years of therapy, a study found. The treatment was especially effective in those without brain lesions before treatment.
June 18, 2020 News by InĆŖs Martins, PhD Obesity Linked to Faster Optic Nerve Atrophy, Study Finds Multiple sclerosis (MS) patients who are obese experience faster degeneration in optic nerve tissue than do those of normal weight, an observational study found. Since optic nerve degeneration correlates with greater nerve loss in the brain, measuring changes in this tissue may be a feasible way to determine…
September 26, 2019 News by Marisa Wexler, MS MRI Marker May Be Better at Predicting MS Disease Progression, Study Finds The volume of atrophied (shrunken) regions in the brain, as visible through magnetic resonance imaging (MRI) scans, can predict disease progression in people with multiple sclerosis (MS), new research reveals. The finding was published in the journalĀ Radiology in an article titled, “Atrophied Brain T2 Lesion Volume…
July 3, 2019 News by Patricia Inacio, PhD Rebif Cost-effective and Can Reduce Brain Lesions in RRMS Patients, Data Show Merck KGaA presented new evidence supporting the safety and clinical efficacy of RebifĀ (interferon beta-1a) for relapsing-remitting multiple sclerosis (RRMS) at the 5thĀ Congress of the European Academy of Neurology (EAN), June 29āJuly 2 in Oslo, Norway. The company, known asĀ EMD SeronoĀ in the U.S. and Canada, presented 16…
July 25, 2018 News by Vijaya Iyer, PhD Despite Increased Lesions, No Brain Atrophy Seen in RRMS Patients After Childbirth, Study Reports In women with relapsing-remitting multiple sclerosis (RRMS), there is a significant increase in brain lesion volume after pregnancy, but it is not accompanied by aĀ loss of brain cells, a study suggests. Conducted by researchers at Harvard Medical School, the study, āQuantitative MRI analysis of cerebral lesions and…
June 7, 2018 News by Jose Marques Lopes, PhD Atrophy of Brain Lesions Predicts Disability in MS, 10-year Study Finds Atrophy (shrinkage) of brain lesions correlates with physical disability in patients with multiple sclerosis (MS), new research reports. The study, āAtrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis,ā was published in theĀ Journal of Neuroimaging. Magnetic resonance imaging (MRI) scans are used routinely on MS patients…
February 22, 2018 News by Iqra Mumal, MSc Study Links Degeneration of Deep Gray Matter in Brain to Faster MS Disability Degeneration of the brain’s deep gray matter is associated with more rapid disability in multiple sclerosis patients, a European study shows. The research, āDeep gray matter volume loss drives disability worsening in multiple sclerosis,ā was published in the journal Annals of Neurology. Scientists know that loss…
January 2, 2018 News by Patricia Inacio, PhD Gilenya Halts Brain’s Gray Matter Atrophy in RRMS Patients, Study Suggests Treatment with Gilenya (fingolimod) may limit cerebral gray matter atrophy in relapsing-remitting multiple sclerosis (RRMS) patients, researchers at Boston’s Brigham and Women’s HospitalĀ have found. Their report, āA two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis,ā appeared in the…